Tuberculin shift in patients with chronic inflammatory arthritis and biological therapy
Abstract
Introduction: The blockade of inflammatory mediators produced by biological therapies is associated with an increase of opportunistic infections such as Mycobacterium tuberculosis (MT), so it is recommended to perform the intradermal purified protein derivative test (PPD) before starting such treatment. Given the endemic situation of tuberculosis (TB) in our country and immunosuppression/ anergy of patients with chronic inflammatory arthritis, we wonder whether if it´s necessary to monitor the infection of MT after starting biological treatment.References
I. Listing J, Strangfekd A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52(11):3403-12.
II. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouw-er DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. CID 2004;38:1261-5.
III. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the devel-opment of bactericidal granulomas during BCG infection. Cell 1989;56(5):731-40.
IV. Gómez-Reino JJ, Carmona L, Descalzo MA, Biobadaser Group. Risk of Tuberculosis in patients treated with tu-mor necrosis factor antagonists due to incomplete preven-tion of reactivation of latent infection. Arthritis Rheum 2007;57(5):756-61.
V. 1980-2009- Instituto Nacional de Enfermedades Respira-torias E. Coni. PRO.TB. Doc.Téc. N° 16/09.
VI. Ahmed AR, Blose DA. Delayed-type hypersensitivity skin testing. A review. Arch Dermatol 1983;119(11):934-45.
VII. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64(9):1360-1.
VIII. Menzies D. Interpretation of repeated tuberculin tests boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159(1):15-21.
IX. Abbate E, Ballester D, Barrera L, Brian MC, Echazarreta A, Gaitán C, et al. Consenso Argentino de Tuberculosis. Rev Arg Med Resp 2009;9:61-69.
X. Wang L, Tunner M, Elwood R. A. Meta-analysys of the effect of bacilli Calmette Guerin vaccination on tuberculin test measurements. Torax 2002; 57: 804-9.
XI. Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N, et al. Purified Protein Derivative Response in Juvenile Idiopathic Arthritis. J Rheumatol 2009;36(9):2029-32.
XII. Arnett FC, Edworthy SM, Bloch DA,McShane DJ, Fries JF, Cooper et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24.
XIII. Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, et al. The 2010 American College of Rheumatol-ogy/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis 2010;69(9):1589-95.
XIV. Petty RE, Southwood TR, Manners P, Baum J, Glass D, Goldenberg J, et al, International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001,The Journal of Rheumatology 2004;31(2):390-2.
XV. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68(6):777-83.
XVI. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou C, et al. The Assessment of Spondylo-Arthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70(1):25-31
XVII. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR study group. Classifica-tion criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum. 2006;54(8)2665-73.
XVIII. Anderson P, Gual A, Colon J. Alcohol y atención primaria de la salud: informaciones clínicas básicas para la identifi-cación y el manejo de riesgos y problemas. Washington, D.C.: OPS, © 2008.
XIX. Informe costo de canasta básica Septiembre del 2013, IN-DEC (Instituto Nacional De Estadísticas y Censos).
XX. M aldonado Ficco H, Pérez Alamino R, Schneeberger EE, Maldonado Cocco JA, Citera G. Validación del cues-tionario RAPID3 en una cohorte de pacientes con artritis reumatoidea temprana y establecida, y su correlación con otros índices de actividad. Rev Argent Reumatol 2011;22 (2):31-39.
XXI. Citera G, Maldonado Cocco JA, Moroldo M, Burgos-Var-gas R, Anaya J, López I, et al. Validación de la versión en español de los cuestionarios de capacidad funcional BAS-FI y actividad de la enfermedad BASDAI en pacientes con Espondilitis Anquilosante en cuatro países latinoamerica-nos. Rev Arg Reumatol 1999;10(Supl 1):25.
XXII. Citera G, Arriola MS, Maldonado Cocco JA, Rosemffet MG, Sánchez MM, Goñi MA, et al. Validation and cross cultural adaptation of an argentine spanish version of the health assessment questionnaire disability index. J Clin Rheum 2004;10(3):110-5.
XXIII. Dixon WG, Watson K, Lunt M, Hyrich L, Silman AJ,, British Society for Rheumatology Biologics Register, Rates of Serious Infection, Including Site-Specific and Bacterial Intracellular Infection, in Rheumatoid Arthritis Patients Receiving Anti-Tumor Necrosis Factor Therapy. Arthritis Rheum 2006;54(8):2368-76.
XXIV. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive Conversion of Tuberculin Skin Test and Performance if Interferon Realese Assay to Detect Hidden Tuberculo-sis Infection During Anti-Tumor Necrosis Factor Agent Trial. J Rheumatol 2009;36(10):2158-63.
Copyright (c) 2016 Argentine Journal of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
